This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Circulation: Cardiovascular Interventions, Ahead of Print. BACKGROUND:A high permanent pacemaker implantation (PPI) risk remains a concern of self-expandable transcatheter aorticvalve implantation, despite the continued improvements in implantation methodology. There were no group differences in 30-day all-cause mortality (1.4%
Circulation, Ahead of Print. BACKGROUND:Calcification of the aorticvalve leads to increased leaflet stiffness and consequently results in the development of calcific aorticvalve disease (CAVD). However, the underlying molecular and cellular mechanisms of calcification remain unclear.
Circulation, Volume 150, Issue Suppl_1 , Page A4145296-A4145296, November 12, 2024. Aorticvalve stenosis (AS) is often a contraindication to liver transplantation (LT). Aorticvalve peak velocity (AVVmax) increased steadily as patients neared transplant and dropped significantly immediately after transplantation (Figure 1A).
Circulation, Volume 150, Issue Suppl_1 , Page A4138340-A4138340, November 12, 2024. Background:Calcific AorticValve Disease is a common cardiac condition with no effective medication available; severe cases require surgery. Immunohistochemical staining showed high expression of Cav-1 in calcified aorticvalves.
Circulation: Cardiovascular Interventions, Volume 16, Issue 11 , Page e012966, November 1, 2023. Transcatheter aorticvalve replacement (TAVR) is increasingly being performed in younger and lower surgical risk patients.
Circulation: Cardiovascular Interventions, Ahead of Print. BACKGROUND:Data concerning the outcomes of transcatheter aorticvalve replacement in type 0 bicuspid aortic stenosis (AS) are scarce. Self-expanding transcatheter heart valves were used in the majority of patients (n=1160; 91.4%). Poverall=0.765; 1 year: 1.4%
Circulation: Cardiovascular Interventions, Volume 18, Issue 2 , Page e014523, February 1, 2025. Histological findings in transcatheter aorticvalve leaflets were evaluated. MicroCT imaging was used to evaluate HALT in histology.
Circulation: Cardiovascular Interventions, Ahead of Print. BACKGROUND:Current guidelines recommend surgical aorticvalve replacement (SAVR) for patients with severe aortic stenosis and unfavorable iliofemoral access.
BackgroundCardiac fibrosis is common in patients with severe aortic stenosis and an independent predictor of death. Combined with highsensitivity cardiac troponin T, circulating TIMP1 should be incorporated into risk stratification to identify patients undergoing TAVR who are at a higher risk of death. 95% CI, 2.69.7];P<0.001)
Circulation: Cardiovascular Interventions, Ahead of Print. Some patients with aortic stenosis may require multiple valve interventions in their lifetime, and choosing transcatheter aorticvalve replacement (TAVR) as the initial intervention may be appealing to many.
Circulation: Cardiovascular Imaging, Ahead of Print. BACKGROUND:Bioprosthetic valve dysfunction and reoperations/reinterventions are common after aorticvalve replacement (AVR) with bioprosthetic valves, leading to cycles of left ventricular (LV) pressure overload and unloading.
Circulation, Ahead of Print. The groups were stratified by aorticvalve morphology (BAV, n=589; TAV, n=558). The outcomes of interests were new-onset third-degree AV block or new-onset LBBB during the index hospitalization.
Circulation, Ahead of Print. BACKGROUND:A better understanding of the molecular mechanism of aorticvalve development and bicuspid aorticvalve (BAV) formation would significantly improve and optimize the therapeutic strategy for BAV treatment.
milla1cf Thu, 03/28/2024 - 07:30 March 28, 2024 — Medtronic plc, a global leader in healthcare technology, announced that the United States Food and Drug Administration ( FDA ) has approved the Evolut FX+ transcatheter aorticvalve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. Circulation.
Circulation: Cardiovascular Interventions, Ahead of Print. BACKGROUND:The extent of cardiac damage has been shown to be associated with increased mortality, repeat hospitalization, and decreased quality of life after aorticvalve replacement (AVR).
Greater adverse events were associated with both low and high postprocedural aorticvalve mean gradient extremes following transcatheter aorticvalve implantation (TAVI) for degenerated surgical aorticvalve replacement (SAVR) bioprostheses, indicating a complex and nonlinear relationship between gradients and clinical outcomes, according to a recent (..)
Circulation: Cardiovascular Quality and Outcomes, Ahead of Print. BACKGROUND:Although Medicare Advantage (MA) plans provide coverage to >50% of Medicare beneficiaries, it is unclear whether MA claims can be used similarly to Medicare Fee-For-Service (FFS) claims for clinical outcomes assessment.
Circulation: Cardiovascular Imaging, Volume 17, Issue 12 , Page e017425, December 1, 2024. BACKGROUND:In aortic stenosis, the myocardium responds with left ventricular hypertrophy, which is characterized by increased left ventricular mass due to cellular hypertrophy and extracellular matrix expansion. weeks post-AVR.
Objectives This study aimed to evaluate the prognostic value of coronary microvascular dysfunction (CMD) at long term after transcatheter aorticvalve implantation (TAVI) and to explore its relationship with extravalvular cardiac damage (EVCD). CMD was defined as IMR angio ≥30 units.
Circulation, Ahead of Print. Pathogeneses include connective tissue disorders, smooth muscle contraction disorders, and congenital heart disease, including bicuspid aorticvalve, among others. The American Heart Association has published guidelines for diagnosis and management of thoracic aortic disease.
Circulation, Ahead of Print. Background:The optimal treatment in patients with severe aortic stenosis (AS) and small aortic annulus (SAA) remains to be determined.
Circulation: Cardiovascular Interventions, Ahead of Print. Background:Atherosclerotic cardiovascular disease (ASCVD) is highly prevalent in patients with severe aortic stenosis undergoing transcatheter aorticvalve replacement (TAVR).
Circulation, Ahead of Print. Severe disease is managed with valve replacement procedures, which entail high health care–related costs and postprocedural morbidity and mortality. Valvular heart disease is a common cause of morbidity and mortality worldwide and has no effective medical therapy.
Circulation, Ahead of Print. Background: Atrial fibrillation (AF) is common in patients undergoing transcatheter aorticvalve replacement (TAVR) and is associated with increased risk of bleeding and stroke.
Circulation: Cardiovascular Imaging, Ahead of Print. BACKGROUND:Patients with paradoxical low-flow, low-gradient severe aortic stenosis exhibit low transvalvular flow rate (Q), while maintaining preserved left ventricular ejection fraction. Subgroups were based on MR severity (severe and nonsevere). P<0.001). P<0.001).
Lp(a) is emerging as an important, yet under-recognized, potential risk factor for cardiovascular disease due to its ability to promote the development of plaques within artery walls, clot formation and aorticvalve calcification. Circulation. Arnett DK et al. 2019 Sep 10;140(11):e563-e595. doi: 10.1161/CIR.0000000000000677.
Circulation, Ahead of Print. Background: Symptomatic severe aortic stenosis (AS) remains undertreated with high resultant mortality despite increased growth and availability of aorticvalve replacement (AVR) since the advent of transcatheter therapies. cm2were enrolled. cm2were enrolled. with EPN versus 37.2%
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
76 
Let's personalize your content